Durable Survival Outcomes in Advanced Melanoma With Neoadjuvant Dual Immunotherapy

(MedPage Today) — The vast majority of patients with stage III resectable melanoma treated with neoadjuvant and adjuvant dual immunotherapy — nivolumab (Opdivo) and relatlimab (Opdualag) — remained alive and disease-free after almost 4 years…